Smo1

Phase 3

SSANGMYUNG innovation

Smo1 is one of 6 therapeutic programs targeting Retinal Vein Occlusion. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Retinal Vein OcclusionRecruiting

Retinal Vein OcclusionPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Retinal Vein Occlusion

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

6 2

Niacor

Celestone

Smo1

SSANGMYUNG innovation

Phase 3

1 5

Anti-VEGF Drug

FFirst Affiliated Hospital of Chongqing Medical University

Phase 3

1 6

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Retinal Vein Occlusion

NCT07708142

Clinical

Trials by Indication[1]

Retinal Vein Occlusion1 trial

A Multicenter, Randomized, Double-blind, Parallel Design, Active-controlled Phase 3 Study to Determine Efficacy and Safety Following Administration of SMO1 in Patients With Retinal Vein Occlusive Macular Edema

Recruiting·SSANGMYUNG innovation·Phase 3·NCT07708142·312 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Smo1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Smo1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — SANGMYUNG innovation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SSANGMYUNG innovation

Smo1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Retinal Vein Occlusion1 trial

References

Drug Info

Quick Facts

Related News